Cargando…

Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

BACKGROUND: The Headache Impact Test (HIT)-6 was developed and has been validated in patients with various types of headache. The objective of this study was to report the psychometric properties of the HIT-6 among patients with chronic migraine. METHODS: Data came from two international, multicente...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rendas-Baum, Regina, Yang, Min, Varon, Sepideh F, Bloudek, Lisa M, DeGryse, Ronald E, Kosinski, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243819/ https://www.ncbi.nlm.nih.gov/pubmed/25080874 http://dx.doi.org/10.1186/s12955-014-0117-0

Ejemplares similares

Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
por: Yang, Min, et al.
Publicado: (2011)

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
por: Rendas-Baum, Regina, et al.
Publicado: (2012)

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
por: Lipton, Richard B, et al.
Publicado: (2016)

Reliability and Validity of Turkish Version of Headache Impact Test (HIT-6) in Patients with Migraine
por: DİKMEN, Pınar Yalinay, et al.
Publicado: (2020)

Systematic Review of Migraine Prophylaxis Adherence and Persistence
por: Hepp, Zsolt, et al.
Publicado: (2014)

Headache-related health resource utilisation in chronic and episodic migraine across six countries
por: Sanderson, Joanna C, et al.
Publicado: (2013)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Headache symptoms of the PREEMPT population
por: Dodick, DW, et al.
Publicado: (2013)

Headache Impact Test-6 (HIT-6) Scores for Migraine Patients: Their Relation to Disability as Measured from a Headache Diary
por: Shin, Hae Eun, et al.
Publicado: (2008)

Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine
por: Houts, Carrie R., et al.
Publicado: (2020)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
por: Aurora, SK, et al.
Publicado: (2013)

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
por: Diener, HC, et al.
Publicado: (2013)

Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review
por: Houts, Carrie R., et al.
Publicado: (2019)

The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
por: Silberstein, S, et al.
Publicado: (2013)

Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population
por: Ghorbani, Abbas, et al.
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)

Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
por: Rothrock, JF, et al.
Publicado: (2013)

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
por: Matharu, Manjit, et al.
Publicado: (2017)

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
por: Silberstein, Stephen D, et al.
Publicado: (2015)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
por: Houts, Carrie R., et al.
Publicado: (2020)

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)
por: Haywood, Kirstie L, et al.
Publicado: (2021)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
por: Aurora, SK, et al.
Publicado: (2014)

Reliability and validity of Hindi translation of the migraine disability assessment and headache impact test-6 questionnaires
por: Juyal, Ratish, et al.
Publicado: (2010)

Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76)
por: Rendas-Baum, Regina, et al.
Publicado: (2021)

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
por: Lipton, Richard B, et al.
Publicado: (2015)

Video head impulse test (vHIT) in migraine dizziness
por: ElSherif, Mayada, et al.
Publicado: (2018)

Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials
por: Rendas-Baum, Regina, et al.
Publicado: (2017)

Outcomes of topiramate for prophylaxis of chronic migraine headache
por: Ahmed, Khawar, et al.
Publicado: (2022)

Evaluation of Relationship Between Sleep Bruxism and Headache Impact Test-6 (HIT-6) Scores: A Polysomnographic Study
por: Martynowicz, Helena, et al.
Publicado: (2019)

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
por: Rendas-Baum, Regina, et al.
Publicado: (2011)

Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative
por: Haywood, Kirstie, et al.
Publicado: (2021)

Caffiene in Headache, (Migraine.)
por: Smith, T. Curtis
Publicado: (1874)

Migraine headache in Sudan
por: Ibrahim, Etedal Ahmed A., et al.
Publicado: (2021)

Migraine and Sick Headache
Publicado: (1905)

Psychometric validation of the revised SCOPA-Diary Card: expanding the measurement of non-motor symptoms in parkinson's disease
por: Rendas-Baum, Regina, et al.
Publicado: (2011)

Validation of The 3-Question Headache Screen in The Diagnosis of Migraine in Nigeria
por: Wahab, Kolawole, et al.
Publicado: (2016)

Validation of the “My Headache Checker” that includes osmophobia in the diagnosis of migraine
por: Matsushita, Masahide, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a3tujg4eieagjubfsa87oqg76u